natgillin/translations-raw huggingface dataset:
The safety and efficacy of palonosetron in children aged less than 1 month have not been established.
Sigurnost primjene i djelotvornost palonosetrona u djece mlađe od 1 mjeseca nisu ustanovljene.
Ten percent of patients have a mean terminal elimination halflife greater than 100 hours.
Deset posto bolesnika ima terminalni poluvijek eliminacije dulji od 100 sati.
Children and Adolescents (aged 1 month to 17 years) The doctor will decide the dose, depending on bodyweight, however the maximum dose is 1500 micrograms.
Djeca i adolescenti (u dobi od 1 mjeseca do 17 godina) Liječnik će odrediti dozu ovisno o tjelesnoj težini, ali najveća doza je 1500 mikrograma.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.
Ako ste trudni ili dojite, mislite da biste mogli biti ili planirate imati dijete, obratite se svom liječniku ili ljekarniku za savjet prije nego uzmete bilo ovaj lijek.
• At the request of the European Medicines Agency; Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
• uoči svake izmjene sustava za upravljanje rizicima, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera korist/rizik, odnosno kada je omjer korist/rizik rezultat ostvarenja nekog važnog cilja (u smislu farmakovigilancije ili smanjenja rizika).
A specific thorough QT/QTc study was conducted in healthy volunteers for definitive data demonstrating the effect of palonosetron on QT/QTc (see section 5.1).
Temeljito ispitivanje upravo QT/QTc intervala, provedeno je u zdravih dobrovoljaca kako bi se dobili definitivni podaci o učinku palonosetrona na QT/QTc (vidjeti dio 5.1).
Palonosetron is not mutagenic.
Palonosetron nije mutagen.
• if you have an imbalance of certain minerals in your blood such as potassium and magnesium which has not been treated.
- Ako imate neravnotežu nekih minerala u krvi kao npr. kalija i magnezija, a to nije bilo liječeno.
This leaflet was last revised in month YYYY.
Ova uputa je zadnji puta revidirana u mjesec/GGGG.
Clearance c, L/h/kg
Klirens c, l/h/kg
Palonosetron Hospira should be injected over 30 seconds.
Palonosetron Hospira treba ubrizgati tijekom 30 sekundi.
Manufacturer Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, United Kingdom
Proizvođač Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, Ujedinjeno Kraljevstvo
Via Fosse Ardeatine, 2, 20060, Liscate (MI) Italy
Via Fosse Ardeatine, 2, 20060, Liscate (MI) Italija
It is not known whether Palonosetron Hospira will cause any harmful effects when used during pregnancy.
Nije poznato hoće li Palonosetron Hospira prouzročiti bilo kakve štetne učinke ako se primjenjuje tijekom trudnoće.
Hypokalemia and hypomagnesemia should be corrected prior to 5-HT3 -antagonist administration.
Hipokalijemiju i hipomagnezijemiju treba ukloniti prije primjene antagonista 5-HT3.
Therefore, palonosetron should not be used in pregnant women unless it is considered essential by the physician.
Stoga palonosetron ne smiju uzimati trudnice, osim ako liječnik smatra da je to prijeko potrebno.
• high levels of the pigment bilirubin in the blood
• visoke razine pigmenta bilirubina u krvi
Package leaflet: Information for the patient
Uputa o lijeku: Informacija za korisnika
A lower bound greater than -15 % demonstrates non-inferiority between palonosetron and comparator.
Donja granica veća od -15% pokazuje neinferiornost između palonosetrona i usporednog lijeka.
As there are no data concerning palonosetron excretion in breast milk, breast-feeding should be discontinued during therapy.
S obzirom da ne postoje podaci o izlučivanju palonosetrona u majčino mlijeko, za vrijeme terapije treba prekinuti dojenje.
The effect of palonosetron on QTc interval was evaluated in a double blind, randomised, parallel, placebo and positive (moxifloxacin) controlled trial in adult men and women.
Učinak palonosetrona na QTc interval procijenjen je u dvostruko slijepom, randomiziranom, usporednom, placebom i pozitivno (moksifloksacin) kontroliranom ispitivanju u odraslih muškaraca i žena.
Palonosetron Hospira belongs to a group of medicines known as serotonin (5HT3) antagonists.
Palonosetron Hospira pripada skupini lijekova poznatih kao antagonisti serotonina (5HT3).
• change in the colour of the vein and/or veins becoming larger
• promjene boje vene i/ili proširenje vena
Pfizer Service Company BVBA, Hoge Wei 10, 1930 Zaventem, Belgium
Pfizer Service Company BVBA, Hoge Wei 10, 1930 Zaventem, Belgija
In clinical studies in adults at a dose of 250 micrograms (total 633 patients) the most frequently observed adverse reactions, at least possibly related to palonosetron, were headache (9 %) and constipation (5 %).
U kliničkim ispitivanjima u odraslih s dozom od 250 mikrograma (ukupno 633 bolesnika) najčešće opažene nuspojave, barem moguće povezane s primjenom palonosetrona, bile su glavobolja (9%) i konstipacija. (5%).
However, as for other 5-HT3 antagonists, caution should be exercised in the use of palonosetron in patients who have or are likely to develop prolongation of the QT interval.
Međutim, kao i za druge antagoniste 5-HT3, potreban je oprez pri primjeni palonosetrona u bolesnika koji imaju produljenje QT intervala ili je vjerojatno da će se ono u njih pojaviti.
• if you have a personal or family history of alterations in heart rhythm (QT prolongation);
- Ako imate osobnu ili obiteljsku anamnezu promjena srčanog ritma (produljenje QT intervala).
Palonosetron is a selective high-affinity receptor antagonist of the 5HT3 receptor.
Palonosetron je selektivni antagonist visokog afiniteta za 5HT3 receptor.
Avara Liscate Pharmaceutical Services S.p.A., Via Fosse Ardeatine, 2, 20060, Liscate (MI), Italy
Avara Liscate Pharmaceutical Services S.p.A., Via Fosse Ardeatine, 2, 20060, Liscate (MI), Italija
L/kg
g/kg
While this study demonstrated that paediatric patients require a higher palonosetron dose than adults to prevent chemotherapy-induced nausea and vomiting, the safety profile is consistent with the established profile in adults (see section 4.8).
Iako je ovo ispitivanje pokazalo da je za sprječavanje mučnine i povraćanja izazvanih kemoterapijom pedijatrijskim bolesnicima potrebna veća doza palonosetrona nego odraslim bolesnicima, profil sigurnosti podudara se s profilom ustanovljenim u odraslih (vidjeti dio 4.8).
Adverse reactions were evaluated in paediatric patients receiving palonosetron for up to 4 chemotherapy cycles.
Nuspojave su procijenjene u pedijatrijskih bolesnika koji su primali palonosetron do 4 kemoterapijska ciklusa.
Palonosetron was non-inferior versus the comparators in the acute phase of emesis both in moderately and highly emetogenic setting.
Palonosetron nije bio inferioran u usporedbi s usporednim lijekovima u akutnoj fazi emeze u umjereno i visoko emetogenim okolnostima.
Although comparative efficacy of palonosetron in multiple cycles has not been demonstrated in controlled clinical studies, 875 patients enrolled in the three phase 3 trials continued in an open label safety study and were treated with palonosetron 750 micrograms for up to 9 additional cycles of chemotherapy.
Iako se u kontroliranim kliničkim ispitivanjima nije pokazala usporedna djelotvornost palonosetrona u više ciklusa, 875 bolesnika uključena u tri ispitivanja faze 3 nastavila su sudjelovati u otvorenom ispitivanju sigurnosti i liječeni su palonosetronom 750 mikrograma do 9 dodatnih ciklusa kemoterapije.
Palonosetron is eliminated by dual route, about 40 % eliminated through the kidney and with approximately 50 % metabolised to form two primary metabolites, which have less than 1 % of the 5HT3 receptor antagonist activity of palonosetron.
Palonosetron se izlučuje dvojnim putem; oko 40% uklanja se bubregom a približno 50% metaboliziranog lijeka tvori dva primarna metabolita, koji imaju manje od 1% djelovanja palonosetrona kao antagonista 5HT3 receptora.
The underlying mechanisms are not fully understood, but because of the high doses employed and since Palonosetron Hospira is intended for single application in humans, these findings are not considered relevant for clinical use.
Osnovni mehanizmi nisu potpuno poznati, ali budući da se radi o visokim dozama lijeka Palonosetron Hospira je namijenjen za jednokratnu primjenu u ljudi, ti se nalazi ne smatraju značajnima za kliničku uporabu.
It is not known if Palonosetron Hospira is found in breast milk.
Nije poznato može li se Palonosetron Hospira naći u majčinu mlijeku.
Given the pre-specified noninferiority margin of -10%, the stratum adjusted Mantel-Haenszel statistical non-inferiority confidence interval for the difference in the primary endpoint, complete response (CR), was [-10.5, 1.7%], therefore non-inferiority was not demonstrated.
Uz prethodno određenu granicu neinferiornosti od -10%, prema Mantel-Haenszelovom statističkom intervalu pouzdanosti za neinferiornost prilagođenom za slojeve za razliku u primarnom ishodu, potpuni odgovor (CR), bio je [-10,5, 1,7%]; dakle, neinferiornost nije dokazana.
In clinical studies the following adverse reactions (ARs) were observed as possibly or probably related to palonosetron.
U kliničkim ispitivanjima opažene su sljedeće nuspojave koje su možda ili vjerojatno bile povezane s primjenom palonosetrona.
The proportion of patients without emesis during 0-72 hours post-operatively was similar after palonosetron 1 μg/kg or 3 μg/kg (88% vs 84%).
Udio bolesnika bez emeze u trajanju od 0-72 sata poslije operacije bio je sličan nakon primjene palonosetrona 1 µg/kg ili 3 µg/kg (88% naspram 84%).
High doses of palonosetron (each dose causing at least 30 times the human therapeutic exposure) applied daily for two years caused an increased rate of liver tumours, endocrine neoplasms (in thyroid, pituitary, pancreas, adrenal medulla) and skin tumours in rats but not in mice.
Visoke doze palonosetrona (jedna doza najmanje 30 puta veća od doze primijenjene u terapijske svrhe u čovjeka) primijenjene svakodnevno tijekom dvije godine prouzročile su povećanu učestalost tumora jetre, neoplazme endokrinog sustava (u štitnjači, hipofizi, gušterači, nadbubrežnoj žlijezdi) i tumore kože u štakora ali ne u miševa.
Noninferiority criteria were met if the lower bound of the 97.5% confidence interval for the difference in Complete Response rates of intravenous palonosetron minus intravenous ondansetron was larger than -15%.
Kriteriji neinferiornosti bili su ispunjeni ako je donja granica intervala pouzdanosti od 97,5%, za razliku u stopama potpunog odgovora za intravenski palonosetron minus intravenski ondansetron, bila veća od -15%.
There are limited data on the use of palonosetron in the prevention of nausea and vomiting in children under 2 years of age.
Postoje ograničeni podaci o primjeni palonosetrona za sprječavanje mučnine i povraćanja u djece mlađe od 2 godine.
A doctor or nurse will normally inject Palonosetron Hospira about 30 minutes before the start of chemotherapy.
Liječnik ili medicinska sestra će Vam ubrizgati Palonosetron Hospira otprilike 30 minuta prije početka kemoterapije.
Dialysis studies have not been performed, however, due to the large volume of distribution, dialysis is unlikely to be an effective treatment for Palonosetron Hospira overdose.
Ispitivanja dijalize nisu bila provedena, međutim, zbog velikog volumena distribucije, dijaliza se ne čini djelotvornim liječenjem za predoziranje lijekom Palonosetron Hospira.
Palonosetron Hospira is used for the prevention of nausea and vomiting associated with cancer chemotherapy in adults, adolescents and children over one month of age.
Palonosetron Hospira se koristi za sprječavanje mučnine i povraćanja povezanih s kemoterapijom raka u odraslih bolesnika, adolescenata i djece starije od mjesec dana.
CYP2D6 inducers and inhibitors.
Induktori i inhibitori CYP2D6
HOSPIRA Enterprises B.V., Randstad 22-11, 1316 BN Almere, The Netherlands
HOSPIRA Enterprises B.V., Randstad 22-11, 1316 BN Almere, Nizozemska
Efficacy after palonosetron 10 μg/kg compared to palonosetron 3 μg/kg was 54.1% and 37.1% respectively.
Djelotvornost nakon palonosetrona 10 µg/kg u usporedbi s palonosetronom 3 µg/kg bila je 54,1% odnosno 37,1%.
It is not recommended to receive Palonosetron Hospira in the days following chemotherapy unless you are receiving another chemotherapy cycle.
Ne preporučuje se primjenjivati Palonosetron Hospira u dane nakon kemoterapije, osim ako primate sljedeći ciklus kemoterapije.
When the dose was increased from 10 μg/kg to 20 μg/kg a dose-proportional increase in mean AUC was observed.
Kada je doza povećana s 10 µg/kg na 20 µg/kg opažen je porast srednje vrijednosti AUC-a proporcionalan dozi.
Efficacy was based on demonstrating non-inferiority of intravenous palonosetron compared to intravenous ondansetron.
Djelotvornost se temeljila na dokazivanju neinferiornosti intravenski primijenjenog palonosetrona u usporedbi s intravenskim ondansetronom.
Allergic reactions to Palonosetron Hospira.
Alergijske reakcije na Palonosetron Hospira.
Fertility There are no data concerning the effect of palonosetron on fertility.
Plodnost Nema podataka o učinku palonosetrona na plodnost.
The primary efficacy endpoint, Complete Response (CR: no vomiting, no retching, and no antiemetic rescue medication) during the first 24 hours postoperatively was achieved in 78.2% of patients in the palonosetron group and 82.7% in the ondansetron group.
Primarni ishod djelotvornosti, potpuni odgovor (CR: izostanak povraćanja, dizanja želuca i bez primjene antiemetičkog simptomatskog lijeka) tijekom prva 24 sata poslije operacije bilo je postignuto u 78,2% bolesnika u skupini koja je primala palonosetron i 82,7% u skupini koja je primala ondansetron.
Dolasetron 100 milligrams (n= 191)
Dolasetron 100 miligrama (n = 191)
There is no experience of palonosetron in human pregnancy.
Nema iskustva s palonosetronom u trudnoći u ljudi.
The objective was to evaluate the ECG effects of IV administered palonosetron at single doses of 0.25, 0.75 or 2.25 mg in 221 healthy subjects.
Cilj je bio procijeniti učinke i.v. primijenjenog palonosetrona u jednostrukim dozama od 0,25, 0,75 ili 2,25 mg na EKG 221 zdravog ispitanika.
While the terminal elimination half-life and mean systemic exposure of palonosetron is increased in the subjects with severe hepatic impairment, this does not warrant dose reduction.
Iako su terminalni poluvijek eliminacije i prosječna sistemska izloženost palonosetronu povećani u ispitanika s teškim oštećenjem jetre, smanjenje doze nije potrebno.
Palonosetron Hospira will be given as a slow infusion into a vein.
Palonosetron Hospira će biti primijenjen u obliku spore infuzije u venu.
Pharmacokinetic simulations indicate that the overall exposure (AUC0-∞) of 0.25 mg intravenous palonosetron administered once daily for 3 consecutive days was similar to a single intravenous dose of 0.75 mg, although Cmax of the 0.75 mg single dose was higher.
Farmakokinetičke simulacije pokazuju da je sveukupna izloženost (AUC0-) dozi od 0,25 mg palonosetrona intravenski primijenjenog jedanput na dan tijekom 3 uzastopna dana, bila slična jednoj intravenskoj dozi od 0,75 mg, iako je Cmax jedne doze od 0,75 mg bio viši.
What Palonosetron Hospira is and what it is used for
Što je Palonosetron Hospira i za što se koristi
• elevated moods or feelings of anxiousness
• pretjerano raspoloženje ili osjećaji tjeskobe
• if you are allergic to palonosetron or any of the other ingredients of this medicine (listed in section 6).
Nemojte primjenjivati Palonosetron Hospira : - ako ste alergični na palonosetron ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
At all dose levels tested, palonosetron did not induce clinically relevant prolongation of the QTc interval.
Pri svim ispitivanim dozama, palonosetron nije izazvao klinički značajno produljenje QTc intervala.
Hepatic impairment does not significantly affect total body clearance of palonosetron compared to the healthy subjects.
Oštećenje funkcije jetre ne utječe značajno na ukupni tjelesni klirens palonosetrona u usporedbi sa zdravim ispitanicima.
The following common or uncommon adverse reactions were reported for palonosetron, none were reported at a frequency of >1%.
Sljedeće nuspojave su prijavljene kao česte i manje česte tijekom primjene palonosterona, nije bilo prijavljenih s učestalošću >1%.
Following single dose intravenous infusion of Palonosetron 20 μg/kg, peak plasma concentrations (CT) reported at the end of the 15 minute infusion were highly variable in all age groups and tended to be lower in patients < 6 years than in older paediatric patients.
Nakon jednokratne intravenske infuzije palonosetrona u dozi od 20 µg/kg, vršne koncentracije u plazmi (CT) zabilježene na kraju 15-minutne infuzije bile su visoko varijabilne u svim dobnim skupinama i u bolesnika u dobi <6 godina kretale su se u nižim vrijednostima nego u starijih pedijatrijskih bolesnika.
Palonosetron Hospira should be used only before chemotherapy administration.
Palonosetron Hospira treba primjenjivati samo prije kemoterapije.
Since the 97.5% confidence interval (stratum adjusted Mantel-Haenszel test) of the difference in CR0-24h between palonosetron 20 μg/kg and ondansetron was [-11.7%, 12.4%], the 20 μg/kg palonosetron dose demonstrated non-inferiority to ondansetron.
Budući da je interval pouzdanosti od 97,5% (MantelHaenszelov test prilagođen za slojeve) za razliku u CR0-24h između palonosetrona u dozi od 20 µg/kg i ondansetrona iznosio [-11,7%, 12,4%], doza palonosetrona od 20 µg/kg dokazala je neinferiornost prema ondansetronu.
Do not use this medicine after the expiry date which is stated on the vial and carton after ‘EXP'.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na bočici i kutiji iza 'Rok valjanosti' ili kratice ‘EXP'.
• weakness, tiredness, fever or flu like symptoms
• slabost, umor, vrućica ili simptomi poput gripe
The pivotal studies were not designed to assess efficacy of palonosetron in delayed onset nausea and vomiting.
Ključna ispitivanja nisu bila osmišljena da bi procijenila djelotvornost palonosetrona u odgođenom početku mučnine i povraćanja.
Palonosetron Hospira is indicated in adults for:
Palonosetron Hospira je u odraslih indiciran za:
Palonosetron Hospira is indicated in paediatric patients 1 month of age and older for:
Palonosetron Hospira je indiciran u pedijatrijskih bolesnika u dobi od 1 mjeseca i starijih za:
In the unlikely event of overdose with Palonosetron Hospira, this should be managed with supportive care.
U vrlo malo vjerojatnom slučaju predoziranja Palonosetron Hospirom, treba pristupiti potpornom liječenju.
Since palonosetron may induce dizziness, somnolence or fatigue, patients should be cautioned when driving or operating machines.
Budući da palonosetron može izazvati omaglicu, somnolenciju ili umor, bolesnike treba na to upozoriti kada upravljaju vozilima ili rukuju strojevima.
Common (may affect up to 1 in 10 people): • headache
Često (mogu se javiti u do 1 na 10 osoba): • glavobolja
Palonosetron is mainly metabolised by CYP2D6, with minor contribution by CYP3A4 and CYP1A2 isoenzymes.
Palonosetron se uglavnom metabolizira pomoću enzima CYP2D6, uz manji doprinos izoenzima CYP3A4 i CYP1A2.
• SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine.
• inhibitore ponovne pohrane serotonina i noradrenalina (SNRI) koji se koriste za liječenje depresije i/ili tjeskobe, uključujući venlafaksin, duloksetin.
In the palonosetron 10 μg/kg, 20 μg/kg and ondansetron groups, the proportion of patients with CR0-24h was 54.2%, 59.4% and 58.6%.
U skupinama koje su primale palonosetron 10 µg/kg i 20 µg/kg te u skupini koja je primala ondansetron, udio bolesnika s potpunim odgovorom CR0-24h bio je 54,2%, 59,4% i 58,6%.
• electrocardiogram abnormalities (QT prolongation)
• abnormalnosti elektrokardiograma (produljenje QT intervala).
In a clinical study, no significant pharmacokinetic interaction was shown between a single intravenous dose of palonosetron and steady state concentration of oral metoclopramide, which is a CYP2D6 inhibitor.
U kliničkom ispitivanju nije ustanovljena značajna farmakokinetička interakcija između jedne intravenske doze palonosetrona i koncentracije oralnog metoklopramida, inhibitora CYP2D6, u stanju dinamičke ravnoteže.
Corticosteroids Palonosetron has been administered safely with corticosteroids.
Kortikosteroidi Palonosetron se sigurno primjenjivao s kortikosteroidima.
Table 4: Pharmacokinetic Parameters in Paediatric Cancer Patients following intravenous infusion of palonosetron at 20 μg/kg over 15 min and in Adult Cancer Patients receiving 3 and 10 μg/kg palonosetron doses via intravenous bolus.
Tablica 4: Farmakokinetički parametri u pedijatrijskih bolesnika s karcinomom nakon intravenske infuzije palonosetrona u dozi od 20 µg/kg tijekom 15 minuta i u odraslih bolesnika s karcinomom koji su primili palonosetron u dozi od 3 i 10 µg/kg u intravenskoj bolus injekciji
• SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram;
• selektivne inhibitore ponovne pohrane serotonina (SSRI) koji se koriste za liječenje depresije i/ili tjeskobe, uključujući fluoksetin, paroksetin, sertralin, fluvoksamin, citalopram, escitalopram
Non-clinical studies indicate that palonosetron, only at very high concentrations, may block ion channels involved in ventricular de- and re-polarisation and prolong action potential duration.
Neklinička ispitivanja pokazuju da palonosetron samo u vrlo visokim koncentracijama može blokirati ionske kanale uključene u ventrikularnu depolarizaciju i repolarizaciju te produljiti trajanje akcijskog potencijala.
In a population pharmacokinetic analysis, it has been shown that there was no significant effect on palonosetron clearance when co-administered with CYP2D6 inducers (dexamethasone and rifampicin) and inhibitors (including amiodarone, celecoxib, chlorpromazine, cimetidine, doxorubicin, fluoxetine, haloperidol, paroxetine, quinidine, ranitidine, ritonavir, sertraline or terbinafine).
U farmakokinetičkoj analizi populacije pokazalo se da ne postoji značajan učinak na klirens palonosetrona kada je primijenjen s induktorima CYP2D6 (deksametazon i rifampicin) i inhibitorima (uključujući amjodaron, celekoksib, klorpromazin, cimetidin, doksorubicin, fluoksetin, haloperidol, paroksetin, kinidin, ranitidin, ritonavir, sertralin ili terbinafin).
Other medicines and Palonosetron Hospira
Drugi lijekovi i Palonosetron Hospira
What Palonosetron Hospira contains
Što Palonosetron Hospira sadrži
20 micrograms/kg (the maximum total dose should not exceed 1500 micrograms) palonosetron administered as a single 15 minute intravenous infusion beginning approximately 30 minutes before the start of chemotherapy.
Doza od 20 mikrograma/kg palonosetrona (maksimalna ukupna doza ne smije prelaziti 1500 mikrograma) daje se u obliku jedne intravenske infuzije u trajanju od 15 minuta, s početkom od približno 30 minuta prije početka kemoterapije.
The efficacy of Palonosetron Hospira in the prevention of nausea and vomiting induced by highly emetogenic chemotherapy may be enhanced by the addition of a corticosteroid administered prior to chemotherapy.
Djelotvornost lijeka Palonosetron Hospira u sprječavanju mučnine i povraćanja izazvanih visoko emetogenom kemoterapijom može se povećati dodatnom primjenom kortikosteroida prije kemoterapije.
Hospira Enterprises B.V. Randstad 22-11 Almere NL-1316 BN The Netherlands
Randstad 22-11 Almere NL-1316 BN Nizozemska
Median half-life was 29.5 hours in overall age groups and ranged from about 20 to 30 hours across age groups after administration of 20 μg/kg.
Medijan poluvijeka iznosio je 29,5 sati u svim dobnim skupinama i nakon primjene doze od 20 µg/kg raspon mu je iznosio od otprilike 20 do 30 sati u svim dobnim skupinama.